Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

Last updated: August 6, 2025 7:25 am

0 Min Read

MedPage Today) — CHICAGO — Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with or without type 2 diabetes, a pair of phase IIIa trials found.
In REDEFINE 1, which included 3,417…

Leave a Reply Cancel reply

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

Refresh Screen

Ads Blocker Detected & This Is Prohibited!!!

Refresh Screen

Top Stories

Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes

Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

I Want You, Doctor, to Run for Office

Stay Connected

Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

Leave a Reply Cancel reply

Related Stories

Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes

I Want You, Doctor, to Run for Office

Simple insulin resistance test may also predict cognitive decline in Alzheimer’s patients

Tinnitus linked to impaired cognitive function

‘5 Years, 10 Years at Most, I’m Going to Retire’: What We Heard This Week

Antibiotics and energy inhibitors effectively kill aggressive melanoma cells by blocking mitochondrial pathways

‘Closed loop’ learning barriers prevent doctors from using life-saving bedside ultrasound

Children born to mothers over 45 face higher risk of premature birth and complications, study finds